Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Zai Lab Limited - American Depositary Shares (NQ:ZLAB)

26.75 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Zai Lab Limited - American Depositary Shares

< Previous 1 2 3 4 5 6 Next >
Zai Lab to Highlight New Data from its Oncology Portfolio at 2023 AACR Annual Meeting
New translational and clinical biomarker data from Zai Lab’s global oncology program ZL-1211 will be featured in a poster presentation (Abstract presentation number: 4531) 
From Zai Lab Limited
Via GlobeNewswire
Zai Lab Partner Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia
From Zai Lab Limited
Via GlobeNewswire
Zai Lab Announces Full-Year 2022 Financial Results and Recent Corporate Updates
From Zai Lab Limited
Via GlobeNewswire
Zai Lab Announces Participation in March Investor Conferences
From Zai Lab Limited
Via GlobeNewswire
Zai Lab to Present Two New Phase 3 Analyses for Niraparib in Ovarian Cancer at the 2023 ESMO Gynaecological Cancers Congress
From Zai Lab Limited
Via GlobeNewswire
3 More Mid-Cap Biotechs The Street Sees Doubling
According to Wall Street research groups, these three mid-cap biotechs have 2x potential. It’s for the investor to decide if the upside justifies the risk. 
Via MarketBeat
Zai Lab Announces NDA Acceptance of Sulbactam-Durlobactam (SUL-DUR) for Infections Caused by Acinetobacter baumannii in China by the NMPA
From Zai Lab Limited
Via GlobeNewswire
Zai Lab to Announce Full-Year Financial Results and Corporate Updates on March 1, 2023
Company to Host Conference Call and Webcast on March 2, 2023, at 8:00 a.m. ET 
From Zai Lab Limited
Via GlobeNewswire
Zai Lab Announces Participation in February Investor Conferences
From Zai Lab Limited
Via GlobeNewswire
Zai Lab Announces NDA for Sulbactam-Durlobactam (SUL-DUR) Granted Priority Review by China’s NMPA
From Zai Lab Limited
Via GlobeNewswire
Zai Lab Announces Inclusion of QINLOCK® (ripretinib) and NUZYRA® (omadacycline) in China’s National Reimbursement Drug List
From Zai Lab Limited
Via GlobeNewswire
Zai Lab Appoints Michel Vounatsos To Its Board of Directors
From Zai Lab Limited
Via GlobeNewswire
Zai Lab and Novocure Announce Pivotal LUNAR Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint
From Zai Lab Limited
Via GlobeNewswire
Zai Lab Announces the Appointment of Dr. Rafael G. Amado as President, Head of Global Oncology Research and Development
From Zai Lab Limited
Via GlobeNewswire
Zai Lab Announces Participation in January Investor Conferences
From Zai Lab Limited
Via GlobeNewswire
Zai Lab Presents Interim Overall Survival Data for ZEJULA® (niraparib) from the NORA Phase 3 Study at the ESMO Virtual Plenary
From Zai Lab Limited
Via GlobeNewswire
Zai Lab Partner Mirati Therapeutics Presents Late-Breaking Results Evaluating Concurrent Adagrasib and Pembrolizumab in First-Line Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
From Zai Lab Limited
Via GlobeNewswire
Zai Lab Announces Third Quarter 2022 Financial Results and Corporate Updates
From Zai Lab Limited
Via GlobeNewswire
Zai Lab to Present New Oncology Research at 2022 Society for Immunotherapy of Cancer Annual Meeting
Poster presentations will highlight Zai’s key internal pipeline programs, ZL-1211 (anti-CLDN18.2 antibody) for gastric cancer and ZL-1218 (anti-CCR8 antibody) for solid tumors 
From Zai Lab Limited
Via GlobeNewswire
Zai Lab Announces the Appointment of Dr. Peter Huang as Chief Scientific Officer
From Zai Lab Limited
Via GlobeNewswire
Zai Lab Announces Participation in November Investor Conferences
From Zai Lab Limited
Via GlobeNewswire
Zai Lab to Announce Third Quarter 2022 Financial Results on November 9, 2022
-- Company to Host Conference Call and Webcast on November 10, 2022, at 8:00 a.m. ET 
From Zai Lab Limited
Via GlobeNewswire
Zai Lab Launches its first Trust Report
Outlines Company’s ESG Strategy through its Trust for Life Commitments 
From Zai Lab Limited
Via GlobeNewswire
Global Cervical Cancer Treatment Market Size Expected to Reach $11 Billion By 2027
Palm Beach, FL – October 6, 2022 – FinancialNewsMedia.com News Commentary – The global Cervical Cancer Treatment market has been expanding for several years and is projected to continue at a growing... 
Via FinancialNewsMedia
Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for TIVDAK® (tisotumab vedotin-tftv)
From Seagen Inc.
Via Business Wire
Novocure and Zai Lab Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer
From Novocure
Via Business Wire
Zai Lab Limited (NASDAQ: ZLAB) Investor Alert: Investigation over Possible Violations of Securities Laws
San Diego, CA -- (SBWIRE) -- 04/25/2022 -- Zai Lab Limited is under investigation over potential securities laws violations by Zai Lab Limited in connection with certain financial statements. 
Via SBWire
INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Zai Lab Limited with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Zai Lab Limited with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
EQUITY ALERT: Rosen Law Firm Encourages Zai Lab Limited Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation – ZLAB
From The Rosen Law Firm, P.A.
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.